Medical approaches to preservation of fertility in female cancer patients

Bibliography

• Jemal A, Siegel R, Xu J, Cancer statistics 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Berkowitz GS, Skovron ML, Lapinski RH, Delayed childbearing and the outcome of pregnancy. N Engl J Med 1990;322:639-64
   Web of Science ®Google Scholar
• Rivkees AS, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988;259:2123-25
   PubMed Web of Science ®Google Scholar
• Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990;61:861-5
   PubMed Web of Science ®Google Scholar
• Ataya K, Rao LV, Lawrence E, Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Catzeddu T, Venturini M. Infertility and pregnancy after breast cancer: current knowledge and future perspectives. Cancer Treat Rev 2006;32:417-22
   PubMed Web of Science ®Google Scholar
• Aebi S, Gelber S, Castiglione-Gertsch M, Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74
   PubMed Web of Science ®Google Scholar
• Pujol P, Hilsenbeck SG, Chamness GC, Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994;75:1601-6
   Google Scholar
• Kroman N, Jensen MB, Wohlfahrt J, Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000;320:474-8
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003;21:28-34
   PubMed Web of Science ®Google Scholar
• Ives A, Saunders C, Bulgara M, Pregnancy after breast cancer: population-based study. BMJ 2007;334:194-8
   PubMed Web of Science ®Google Scholar
• Blakely LJ, Buzdarm AU, Lozada JA, Effects of pregnancy after treatment for breast cancer on survival and risk of recurrence. Cancer 2004;100:465-9
   PubMed Web of Science ®Google Scholar
• Velentgas P, Daling JR, Malone KE, Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 1999;85:2424-32
   PubMed Web of Science ®Google Scholar
• Gelber S, Coates AS, Goldhirsch A, Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 2001;19:1671-5
   PubMed Web of Science ®Google Scholar
• Kroman N, Jensen MB, Melbye M, Should women be advised against pregnancy after breast cancer treatment? Lancet 1997;350:319-22
   PubMed Web of Science ®Google Scholar
• Von Schoultz E, Johansson H, Wilking N, Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995;13:430-4
   PubMed Web of Science ®Google Scholar
• Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: healthy mother effect. Am J Obstet Gynecol 1994;70:818-23
   Google Scholar
• Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990;65:847-50
   PubMed Web of Science ®Google Scholar
• Malamos NA, Stathopoulos GP, Keramopoulos A, Pregnancy and offspring after the appearance of breast cancer. Oncology 1996;53:471-5
   PubMed Web of Science ®Google Scholar
• Ariel IM, Kempner R. The prognosis of patients who become pregnant after mastectomy for breast cancer. Int Surg 1989;74:185-7
   PubMed Web of Science ®Google Scholar
• Mueller BA, Simon MS, Deapen D, Childbearing and survival after breast carcinoma in young women. Cancer 2003;98:1131-40
   PubMed Web of Science ®Google Scholar
• Lee SJ, Schover LR, Partridge AH, American Society of Clinical Oncology recommendations on fertilita preservation in cancer patients. J Clin Oncol 2006;18:2917-31
   Google Scholar
• United Kingdom Children's Cancer Study Group (UKCCSG). Subfertility Risk Consensus Document, 2005. Available from: http://www.ukccsg.org
   Google Scholar
• Children's Oncology Group (COG). Longterm follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, 2004. Available from: http://survivorshipguidelines.org
   Google Scholar
• Scottish Intercollegiate Guidelines Network. Long-term follow-up of survivors of childhood cancer, 2005. Available from: http://www.sign.ac.uk
   Google Scholar
• Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:1086-94
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70
   PubMed Web of Science ®Google Scholar
• Grigg A. The impact of conventional and high-dose therapy for lymphoma on fertility. Clin Lymphoma 2004;5:84-8
   PubMedGoogle Scholar
• Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;34:12-17
   PubMedGoogle Scholar
• Meistrich ML, Vassilopoulou-Sellin R, Lipshultz LI. Gonadal dysfunction, cancer: principles & practice of oncology. 7th edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2005. p. 2560-72
   Google Scholar
• Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-18
   PubMed Web of Science ®Google Scholar
• Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29
   PubMed Web of Science ®Google Scholar
• Venturini M, Del Mastro L, Aitini E, Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005;97:1724-33
   PubMed Web of Science ®Google Scholar
• Levine MN, Bramwell VH, Pritchard KI, Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16:2651-8
   PubMed Web of Science ®Google Scholar
• Swain SM, Jeong JH, Geyer CE, Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010;362:2053-65
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J, Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13
   PubMed Web of Science ®Google Scholar
• Swain SM, Land SR, Ritter MW, Amenorrhea in premenopausal women on the doxorubicin and cyclophosfamide followed by docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009;113:315-20
   PubMed Web of Science ®Google Scholar
• Fornier MN, Modi S, Panageas KS, Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575-9
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Venturini M, Sertoli MR, Amenorrhea indiced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997;43:183-90
   PubMed Web of Science ®Google Scholar
• Jonat W, Kaufmann M, Sauerbrei W, Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J Clin Oncol 2002;20:4628-35
   PubMed Web of Science ®Google Scholar
• Braverman AS, Sawhney H, Tendler A, Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT-) induced amenorrhea in breast cancer (BC). Proc Am Soc Clin Oncol 2002;21:42a
   Google Scholar
• Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64-73
   PubMed Web of Science ®Google Scholar
• Themmen APN. Anti-Mullerian hormone: its role in follicular growth initiation and survival and as ovarian reserve marker. J Natl Cancer Inst Monogr 2005;34:18-21
   Google Scholar
• de Vet A, Laven JS, de Jong FH, Anti-Mullerian hormone serum levels: a putative mark of ovarian aging. Fertil Steril 2002;77:357-62
   PubMed Web of Science ®Google Scholar
• Bath LE, Wallace WH, Shaw MP, Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368-74
   PubMed Web of Science ®Google Scholar
• Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. J Natl Cancer Inst Monogr 2005;34:57-9
   PubMedGoogle Scholar
• Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26:2630-5
   PubMed Web of Science ®Google Scholar
• Colleoni M, Bonetti M, Coates A, Early start of adjuvant chemotherapy may improve out come for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol 2000;18:584-90
   PubMed Web of Science ®Google Scholar
• Recht A, Come SE, Henderson IC, The sequencing of chemotherapy and radiation therapy after conservative surgery for early stage breast cancer. N Engl J Med 1996;334:1356-61
   PubMed Web of Science ®Google Scholar
• Huang JY, Tulandi T, Holzer H, Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril 2008;89:567-72
   PubMed Web of Science ®Google Scholar
• Ataya KM, McKanna JA, Weintraub AM, A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985;45:3651-6
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044-54
   PubMed Web of Science ®Google Scholar
• Kitajima Y, Endo T, Nagasawa K, Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006;147:725-48
   Web of Science ®Google Scholar
• Imai A, Sugiyama M, Furui T, Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007;63:102-6
   PubMed Web of Science ®Google Scholar
• Beek-Fruchter R, Weiss A, Shalev E. GnRH against therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.Hum Reprod Update 2008;14:553-61
   PubMed Web of Science ®Google Scholar
• Waxman JH, Ahmed R, Smith D, Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987;19:159-62
   PubMed Web of Science ®Google Scholar
• Pereyra Pacheco B, Mendez Ribas JM, Milone G, Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-7
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005;34:40-3
   PubMedGoogle Scholar
• Franke HR, Smit WM, Vermes I. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynecol Endocrinol 2005;20:274-8
   PubMed Web of Science ®Google Scholar
• Dann EJ, Epelbaum R, Avivi I, Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005;20:2247-9
   PubMed Web of Science ®Google Scholar
• Somers EC, Marder W, Christman GM, Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Catzeddu T, Boni L, Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006;17:74-8
   PubMed Web of Science ®Google Scholar
• Recchia F, Saggio G, Amiconi G, Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23
   PubMed Web of Science ®Google Scholar
• Giuseppe L, Attilio G, Edoardo DN, Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007;12:141-7
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Nomdedeu B, Camus A, Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 2007;87:702-5
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Avivi I, Eckman A, Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008;89:166-73
   PubMed Web of Science ®Google Scholar
• Huser M, Crha I, Ventruba P, Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 2008;23:863-8
   PubMed Web of Science ®Google Scholar
• Fox KR, Scialla J, Moore H. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Proc Am Soc Clin Oncol 2003;22: abstract 50
   Google Scholar
• Urruticoechea A, Arnedos M, Walsh G, Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008;110(3):411-16
   PubMed Web of Science ®Google Scholar
• Hackshaw A, Baum M, Fornander T, Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009;101:341-9
   PubMedGoogle Scholar
• Sverrisdottir A, Nystedt M, Johansson H, Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561-7
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A, El-Ashry M, Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7
   PubMed Web of Science ®Google Scholar
• Gerber B, Stehle H, Ricardo F, ZORO: a prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37). J Clin Oncol 2009;27(15S): abstract 526
   PubMedGoogle Scholar
• Leonard RC, Adamson D, Anderson R, The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010;28(15S): abstract 590
   PubMedGoogle Scholar
• Del Mastro L, Boni L, Michelotti A, Role of luteinizing hormone-releasing hormone analog (LH-Rha) Triptorelin in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol 2010;28(15S): abstract 528
   Google Scholar